After a busy 2023 on the business development front, Basilea Pharmaceutica Ltd. has started the year by adding more assets to its pipeline with the acquisition of a preclinical antibiotics program from fellow Swiss biotech Spexis AG.
Key Takeaways
- Basilea has been restocking its pipeline through a number of deals
The acquired antibiotics are of a novel class, targeting lipopolysaccharide transport in Gram-negative bacteria, which have been highlighted by the...